Purchase this article with an account.
Simon Leicht, Christian Wertheimer, Raffael Liegl, Anselm Kampik, Kirsten Eibl-Lindner; Vemurafenib as a therapeutic option for treatment of melanoma. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4208.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Uveal melanoma is the most common intraocular tumor. To date, effective pharmacological therapies are lacking. In a set of proof-of-concept experiments, we evaluated the effect of Vemurafenib, a selective BRAF-inhibitor, on A375 melanoma cell line cells.
The human melanoma cell line A375 was incubated with Vemurafenib for 24 hours in different concentrations in the presence of Dulbecco’s MEM medium under standard cell-culture conditions. A Live-dead assay as well as a MTT toxicity assay on confluent cells were performed to exclude toxic concentrations. To determine cell proliferation, 30k cells per well were placed in a 12-well-plate and incubated with Vemurafenib for 24 hours before the tetrazolium dye-reduction assay (MTT test) was performed. After cells were seeded on coated 12-well plates, incubated with Vemurafenib, and rinsed with phosphate-buffered saline, cell proliferation was assessed by the MTT test.
Vemurafenib was an effective inhibitor of human melanoma cell proliferation at nontoxic concentrations in vitro. The 50% inhibitory concentration was close to 500 nM. A Vemurafenib concentration of 5.0 µM accounted for an inhibition of cell proliferation of more than 60%. This effect was dose dependent. No toxic effect was detected compared with controls.
Vemurafenib might have a potential for the treatment of melanoma cells. However, further studies are required to determine if these findings also apply to uveal melanoma cells.
This PDF is available to Subscribers Only